Efficacy and quality of @entity5018 and @entity1443 plus @entity10425 XXXX .

@entity1 @entity5018 @entity1337 @entity158 @entity1443 @entity10425
@entity5018 , 400 mg, was compared with 300 mg @entity1443 plus 30 mg of @entity10425 and placebo in 120 post-orthopedic surgery @entity1 with moderate to severe @entity158 . The study was designed as a double-blind, single-dose, parallel-group analgesic efficacy assay. Estimates of @entity1337 were obtained up to 6 h using categorical and visual analog measures of @entity158 intensity and @entity158 relief. Estimates of selected elements of mood and of sensory and affective components of @entity158 were obtained at 0 and 2 h using contrasting mood word/phrase pairs and a portion of the McGill Pain Questionnaire, respectively. Drugs were distinguishable from placebo in total analgesic effect, and @entity5018 was more effective than @entity1443 plus @entity10425 , especially in terms of duration. While peak effects were comparable, they occurred 1 h later following @entity5018 . Differences among treatments were more discernible using visual analog measures. Side effects were minimal. @entity5018 provided greater improvement in selected elements of mood than @entity1443 plus @entity10425 at comparable levels of @entity158 relief. While @entity158 were most highly associated with @entity158 relief provided by @entity5018 , decreases in the affective component were most highly associated with @entity158 relief following @entity1443 plus @entity10425 . These latter results indicate that mood assessment and the discrimination between sensory and affective components of @entity158 could be particularly useful within analgesic drug assays, especially when comparing analgesics of differing pharmacologic class and when comparing the results of such assays in @entity158 syndromes characterized by differing @entity158 quality.
